ArticleFuture science OA2020
Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency.
Article in Future science OA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 8 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.ESC heart failure · 2026Pooled it
- Ferric Carboxymaltose Among Patients with Heart Failure and Iron Deficiency: An Updated Meta-Analysis of Randomized Controlled Trials.Cardiovascular toxicology · 2026Pooled it
- Intravenous iron therapy for heart failure and iron deficiency: An updated meta-analysis of randomized clinical trials.ESC heart failure · 2025Pooled it
- Impact of Intravenous Iron in patients with heart failure and Iron Deficiency: an updated Meta-analysis of Randomized controlled trials.BMC cardiovascular disorders · 2024Pooled it
- Efficacy of Intravenous Ferric Carboxymaltose in Heart Failure Patients with Iron Deficiency Anemia: A Meta-analysis of 6271 Patients.Clinical drug investigation · 2024Pooled it
- Efficacy of Intravenous Iron in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: A Systematic Review and Meta-Analysis of Randomized Control Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Pooled it
- Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis.European journal of heart failure · 2023Pooled it
- Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency.ESC heart failure · 2023Pooled it
- Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials.JACC. Advances · 2025Article
- Iron Deficiency Treatment in Heart Failure-Challenges and Therapeutic Solutions.Journal of clinical medicine · 2025Review
- Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis.Future science OA · 2024Review
- Iron deficiency and supplementation in heart failure.Nature reviews. Cardiology · 2024Review
- Intravenous iron therapy for patients with iron deficiency and heart failure: a systematic review and meta-analysis of randomized controlled trials.Proceedings (Baylor University. Medical Center) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a very high prevalence of iron deficiency anemia in patients with systolic heart failure. The present study is a prospective, parallel, 1:1 randomized controlled trial of intravenous ferric-carboxy maltose compared with standard of care in patients with heart failure. A total of 70 patients who presented to us with symptomatic chronic heart failure were included and randomly assigned to either groups (35 per group). Post 12 weeks, there were improvements noticed in peak VO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.